Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026986 (
myelodysplastic syndrome
)
14,926
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mutations of
signal-induced proliferation-associated gene 1
(
SIPA1
), a RAP1 GTPase-activating protein, were reported in patients with juvenile myelomonocytic leukemia, a childhood myelodysplastic/myeloproliferative neoplasm (
MDS
/MPN).
Sipa1
deficiency in mice leads to the development of age-dependent MPN. However,
Sipa1
expression in bone marrow (BM) microenvironment and its effect on the pathogenesis of MPN remain unclear. We here report that
Sipa1
is expressed in human and mouse BM stromal cells and downregulated in these cells from patients with MPN or
MDS
/MPN at diagnosis. By using the
Sipa1
-/-
MPN mouse model, we find that
Sipa1
deletion causes phenotypic and functional alterations of BM mesenchymal stem and progenitor cells prior to the initiation of the MPN. Importantly, the altered
Sipa1
-/-
BM niche is required for the development of
MDS
/MPN following transplantation of normal hematopoietic cells. RNA sequencing reveals an enhanced inflammatory cytokine signaling and dysregulated
Dicer1
,
Kitl
,
Angptl1
,
Cxcl12
, and
Thpo
in the
Sipa1
-/-
BM cellular niches. Our data suggest that
Sipa1
expression in the BM niche is critical for maintaining BM niche homeostasis. Moreover,
Sipa1
loss-induced BM niche alterations likely enable evolution of clonal hematopoiesis to the hematological malignancies. Therefore, restoring
Sipa1
expression or modulating the altered signaling pathways involved might offer therapeutic potential for MPN.
...
PMID:
Sipa1
deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm. 2951 90